MedChemExpress MCE - Products
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use.
| Product | Description | |
|---|---|---|
| Rafutrombopag | Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Hetrombopag; SHR-8735. CAS No. 2600513-51-5. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-145589. |  |
| Rafutrombopag (tautomerism) | Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR?expressing cells, including 32D? MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Hetrombopag (tautomerism); SHR-8735 (tautomerism). CAS No. 2114365-78-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-122620. | |
| RAGE 229 | RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2143072-85-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147329. | |
| RAGE antagonist peptide | RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1092460-91-7. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-P2268. | |
| Ragifilimab | Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: INCAGN-1876. CAS No. 2207590-51-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99812. | |
| Ragistomig | Ragistomig can simultaneously target programmed death-ligand 1 (PD-L1) and the 4-1BB receptor. Ragistomig elicits potent anti-tumor T-cell responses without inducing significant toxicity. Ragistomig is applicable for tumor research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ABL503, TJ-L14B. CAS No. 2763222-58-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P990757. | |
| Ralaniten | Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC)[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPI-002. CAS No. 1203490-23-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109070. | |
| Ralaniten triacetate | Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPI-506. CAS No. 1637573-04-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-123875A. | |
| RALA peptide | RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization)[1][2][3]. Uses: Scientific research. Category: Peptides. CAS No. 1613231-49-4. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P5284. | |
| Raleukin | Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Kineret; Anakinra. CAS No. 143090-92-0. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108841. | |
| Ralimetinib | Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LY2228820. CAS No. 862505-00-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-13241A. | |
| Ralimetinib dimesylate | Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LY2228820 dimesylate. CAS No. 862507-23-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13241. | |
| Ralinepag | Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: APD811. CAS No. 1187856-49-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-16751. | |
| Ralmitaront | Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: RO6889450. CAS No. 2133417-13-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109157. | |
| Ralometostat | TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: TNG908. CAS No. 2760481-53-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148419. | |
| Raloxifene | Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Keoxifene; LY156758 free base; LY139481. CAS No. 84449-90-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-13738. | |
| Raloxifene hydrochloride | Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Keoxifene hydrochloride; LY156758; LY139481 hydrochloride. CAS No. 82640-04-8. Pack Sizes: 10 mM * 1 mL in DMSO; 50 mg; 100 mg; 500 mg. Product ID: HY-13738A. | |
| Ralpancizumab | Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1407495-04-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99816. | |
| (R)-(-)-α-Methylhistamine dihydrochloride | (R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM[1][2]. (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats[3][4][5]. Uses: Scientific research. Category: Signaling pathways. CAS No. 75614-89-0. Pack Sizes: 5 mg; 10 mg. Product ID: HY-W014941. | |
| (R)-(-)-α-Phellandrene | (R)-(-)-α-Phellandrene ((-)-α-Phellandrene) is an the (R)-(-)-stereoisomer of α-phellandrene. α-phellandrene is an orally active cyclic monoterpene that attenuates inflammatory response, and induces DNA damage[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: (-)-α-Phellandrene. CAS No. 4221-98-1. Pack Sizes: 1 mL; 10 mM * 1 mL in DMSO; 5 mL. Product ID: HY-N9487. | |
| Raltegravir | Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MK-0518. CAS No. 518048-05-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10353. | |
| Raltegravir potassium | Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MK 0518 potassium. CAS No. 871038-72-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10353A. | |
| Raltitrexed | Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ZD1694; D1694; ICI-D1694. CAS No. 112887-68-0. Pack Sizes: 10 mM * 1 mL in DMSO; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10821. | |
| Raludotatug | Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2610074-56-9. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-P990028. | |
| Raludotatug Deruxtecan | Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: R-DXd; DS-6000. CAS No. 2610074-57-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-164734. | |
| Ramantamig | Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: JNJ-79635322; JNJ-5322. CAS No. 2988886-91-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P991155. | |
| Ramatercept | Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ACE-031. CAS No. 1169766-01-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99818. | |
| Ramatroban | Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BAY u3405. CAS No. 116649-85-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-B0745. | |
| Ramelteon | Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: TAK-375. CAS No. 196597-26-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-A0014. | |
| Ramelteon metabolite M-II | Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist. Uses: Scientific research. Category: Signaling pathways. CAS No. 896736-21-3. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-103005. | |
| Ramelteon metabolite M-II-d3 | Ramelteon metabolite M-II-d3 is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1246812-22-5. Pack Sizes: 1 mg; 5 mg. Product ID: HY-103005S. | |
| (R)-AMG-193 | (R)-AMG-193 is an isomer of AMG 193 (HY-153390). AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC50=0.107 μM), thereby protecting normal cells with wild-type MTAP[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2790567-83-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153390A. | |
| Ramifenazone | Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (NSAID). Ramifenazone has analgesic, antipyretic, anti-inflammatory and antimicrobial activities[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Isopropylaminoantipyrine. CAS No. 3615-24-5. Pack Sizes: 5 mg; 10 mg. Product ID: HY-B1137. | |
| Ramipril | Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: HOE-498. CAS No. 87333-19-5. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 500 mg; 1 g; 5 g. Product ID: HY-B0279. | |
| Ramiprilat | Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat has acute antlhypertensive effect. Ramiprilat can be used for high blood pressure and heart failure research[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: HOE 498 diacid; Ramipril diacid. CAS No. 87269-97-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-A0115. | |
| Ramiprilat-d5 | Ramiprilat-d5 is deuterium labeled Ramiprilat. Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2021255-43-4. Pack Sizes: 1 mg. Product ID: HY-A0115S1. | |
| Ramipril-d5 | Ramipril-d5 is the deuterium labeled Ramipril. Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: HOE-498-d5. CAS No. 1132661-86-9. Pack Sizes: 1 mg. Product ID: HY-B0279S. | |
| Ramoplanin | Ramoplanin is a broad-spectrum lipoglycodepsipeptide antibiotic derived from the Actinoplanes spp with with activity against gram-positive bacteria[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 76168-82-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-129034. | |
| Ramosetron Hydrochloride | Ramosetron (YM060 free base) Hydrochloride is an orally active 5-HT3 antagonist that improves dysphoria, interference with activity and food avoidance. Ramosetron Hydrochloride is promising for research of irritable bowel syndrome with diarrhea[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: YM060. CAS No. 132907-72-3. Pack Sizes: 10 mM * 1 mL in DMSO; 50 mg; 100 mg. Product ID: HY-B0595. | |
| Ramucirumab (anti-VEGFR) | Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 947687-13-0. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P9920A. | |
| Ranibizumab (anti-VEGF) | Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: RG-6321 (anti-VEGF). CAS No. 347396-82-1. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-P9951A. | |
| Ran-IN-1 | Ran-IN-1 is a specific inhibitor of Ran GTPase. Ran-IN-1 selectively induces cytotoxicity and apoptosis in aneuploid ovarian cancer cells and also inhibits DNA repair. Ran-IN-1 exhibits antitumor activity and is useful for research on tumors such as epithelial ovarian cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2301869-11-2. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-173350. | |
| Ranirestat | Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: AS-3201. CAS No. 147254-64-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15314. | |
| Ranitidine hydrochloride | Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 66357-59-3. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 500 mg. Product ID: HY-B0281A. | |
| Ranolazine | Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CVT 303; RS 43285-003. CAS No. 95635-55-5. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 200 mg; 500 mg. Product ID: HY-B0280. | |
| Ranolazine dihydrochloride | Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CVT 303 dihydrochloride; RS 43285. CAS No. 95635-56-6. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 200 mg; 500 mg; 1 g; 5 g. Product ID: HY-17401. | |
| RapaBlock | RapaBlock is a potent, non-immunosuppressive and brain-impermeable FKBP12 ligand[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ZZY05-092. CAS No. 2474076-02-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-153806. | |
| RapaLink-1 | RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1887095-82-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111373. | |
| Rapamycin | Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Sirolimus; AY-22989; NSC 226080. CAS No. 53123-88-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g; 2 g; 5 g. Product ID: HY-10219. | |
| Rapamycin-d3 | Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Sirolimus-d3; AY-22989-d3; NSC 226080-d3. CAS No. 392711-19-2. Pack Sizes: 1 mg. Product ID: HY-10219S. | |
| Rapamycin (GMP) | Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Sirolimus (GMP); AY-22989 (GMP); NSC 226080 (GMP). CAS No. 53123-88-9. Pack Sizes: 10 mg; 50 mg; 100 mg. Product ID: HY-10219G. | |
| Rapamycin (Standard) | Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard). CAS No. 53123-88-9. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10219R. | |
| Raphin1 | Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2022961-17-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-123960. | |
| Raphin1 acetate | Raphin1 acetate is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 acetate binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 acetate crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2242616-04-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-123960A. | |
| Rapirosiran sodium | Rapirosiran (ALN-HSD) sodium is a HSD17β13-targeting siRNA. Rapirosiran sodium can be used for the research of metabolic dysfunction-associated steatohepatitis[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ALN-HSD sodium. CAS No. 2755197-77-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-164221A. | |
| Raptinal | Raptinal, a agent that directly activates caspase-3, initiates intrinsic pathway caspase-dependent apoptosis. Raptinal is able to rapidly induce cancer cell death by directly activating the effector caspase-3, bypassing the activation of initiator caspase-8 and caspase-9[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1176-09-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-121320. | |
| (R)-AS-1 | (R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2506367-95-7. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-168773. | |
| Rasagiline | Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively[1]. Rasagiline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. Alternative Names: (R)-AGN1135; TVP1012. CAS No. 136236-51-6. Pack Sizes: 10 mM * 1 mL in DMSO; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-14605A. | |
| Rasagiline mesylate | Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively[1]. Rasagiline (mesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. Alternative Names: (R)-AGN1135 mesylate; TVP1012 mesylate. CAS No. 161735-79-1. Pack Sizes: 10 mM * 1 mL in Water; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-14605. | |
| Rasburicase | Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 134774-45-1. Pack Sizes: 1 mg. Product ID: HY-108844. | |
| RAS inhibitor Abd-7 | RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2351843-48-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-122862. | |
| Rat CGRP-(8-37) | Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist. Uses: Scientific research. Category: Signaling pathways. CAS No. 129121-73-9. Pack Sizes: 500 μg; 1 mg; 5 mg. Product ID: HY-P0209. | |
| Ravoxertinib | Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GDC-0994. CAS No. 1453848-26-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15947. | |
| Ravuconazole | Ravuconazole (BMS-207147;ER-30346) is an orally available triazole antifungle agent that potently inhibits a wide range of fungi. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BMS-207147; ER-30346. CAS No. 182760-06-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-14272. | |
| Ravulizumab | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ALXN1210. CAS No. 1803171-55-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99365. | |
| Raxatrigine | Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Vixotrigine; GSK-1014802; CNV1014802. CAS No. 934240-30-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-12796. | |
| Raxatrigine hydrochloride | Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Vixotrigine hydrochloride; GSK-1014802 hydrochloride; CNV1014802 hydrochloride. CAS No. 934240-31-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12796A. | |
| Raxibacumab | Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxins deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxins deleterious effects. Raxibacumab can be used for anti-anthrax research[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ABthrax. CAS No. 565451-13-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9957. | |
| (R)-Azetidin-2-ylmethanol | (R)-Azetidin-2-ylmethanol is a drug intermediate for synthesis of various active compounds. Uses: Scientific research. Category: Signaling pathways. CAS No. 209329-11-3. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 250 mg; 500 mg; 1 g; 5 g. Product ID: HY-W061628. | |
| Razuprotafib | Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC50of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC50=36 pM) and HPTPγ (100 pM)[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: AKB-9778. CAS No. 1008510-37-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109041. | |
Would you like to list your products on USA Chemical Suppliers?
Our database is helping our users find suppliers everyday.